Catheter Precision shares surge 55.84% intraday after acquiring Fly Flyte and securing $1.85M in convertible preferred stock funding.

Catheter Precision surged 55.84% intraday, driven by the acquisition of Fly Flyte Inc.’s remaining 80.02% equity, granting full ownership of a revenue-generating, asset-backed regional air platform operating FAA Part 135-certified Cirrus Vision Jets. The company also raised $1.85 million through a private placement of convertible preferred shares, with potential to secure up to $35.56 million in additional funding to support the acquisition, restructure legacy catheter operations, and cover working capital.